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Abstract
The field of public health genomics has matured in the past two decades and is beginning to 
deliver genomic-based interventions for health and health care. In the past few years, the terms 
precision medicine and precision public health have been used to include information from 
multiple fields measuring biomarkers, environmental and other variables to provide tailored 
interventions. In the context of public health, precision implies delivering the right intervention to 
the right population at the right time, with the goal of improving health for all. In addition to 
genomics, precision public health can be driven by “big data” as identified by volume, variety, and 
variability in biomedical, sociodemographic, environmental, geographic, and other information. 
Most current big data applications in health are in elucidating pathobiology and tailored drug 
discovery. We explore how big data and predictive analytics can contribute to precision public 
health by improving public health surveillance and assessment, and efforts to promote uptake of 
evidence-based interventions, by including more extensive information related to place, person and 
time. We use selected examples drawn from child health, cardiovascular disease and cancer to 
illustrate the promise and current methodologic and analytic challenges of big data to fulfill the 
promise of precision public health.
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The term “precision” is increasingly used in medicine (1) and public health (2). Precision 
medicine is often used synonymously with genomic medicine, and precision public health 
has been equated with applications of precision medicine in populations (3). Applications of 
precision medicine (e.g. cancer genomics) are unlikely to lead to improved population 
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health, as targeted interventions benefit only a small subset of the population. Nevertheless, 
as we and others have discussed, there is a bigger role for precision in public health beyond 
genomics (4). Precision public health can be viewed as the delivery of the right intervention 
to the right population at the right time, and includes consideration of social and 
environmental determinants of health (4). As recently stated by Richard Horton, “precision 
public health offers a compelling opportunity to reinvigorate a discipline that has never been 
more important for advancing the health of our most vulnerable and excluded communities. 
Precision public health is about using the best available data to target more effectively and 
efficiently interventions of all kinds to those most in need.” (5)
Increasingly, a large volume of health and non-health related data from multiple sources is 
becoming available that has the potential to drive precision implementation. The term “big 
data” is often used as a buzzword to refer to large data sets that require new approaches to 
manipulation, analysis, interpretation, and integration. (6) Such data include genomic and 
other biomarkers, sociodemographic, environmental, geographic, and other information. Our 
ability to improve population health depends toa large extent on collecting and analyzing the 
best available population level data on burden and causes of disease distribution, as well as 
level of uptake of evidence-based interventions that can improve health for all (6). In this 
commentary, we ask how the emerging abundance of data and its associated predictive 
analytics can contribute to precision public health by including more extensive information 
in public health assessment of disease burden, facilitators and barriers to evidence-based 
intervention implementation and outcome measures, as related to person, place and time. 
(see Table 1 for definitions and examples).
Can big data help better characterize population health outcomes, 
implementation needs and disparities in health and health care?
Public health and implementation scientists explore strategies for improving uptake of 
evidence-based health interventions that target multiple levels (from patient/person level to 
provider, system, community and policy interventions) (7). Implementation gaps and health 
outcomes are usually measured with limited data by place, persons and time.
More Precision Assessment by Place:
The use of big data sources could allow a more in-depth analysis of disease burden and 
implementation gaps and disparities in healthcare systems and population subgroups. For 
example, using small area analysis, we might be able to uncover pockets of disparities in 
implementation of health interventions that are often masked in analysis performed on areas 
such as counties or states. A case in point is the recent local burden of disease analysis on 
child mortality under age 5 across 46 African countries (8). When mortality is analyzed at a 
high spatial resolution, new maps showed major disparities in child mortality even though 
progress in implementation of evidence-based interventions was reported at the country 
level. Similarly, neighborhood deprivation metrics can assess disparities and implementation 
gaps within regions (e.g. wealthy towns may have micro pockets of deprivation (9)). More 
“precision” in geographic, community and health system analysis can pinpoint how best to 
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target interventions to reduce morbidity in difficult to reach subpopulations and help reduce 
disparities.
More Precision Assessment by Person:
Similarly, in characterizing gaps and disparities in implementation and outcomes, personal 
characteristics of patients, providers and policy makers can be further refined beyond the use 
of traditional indicators such as age, gender, race/ethnicity. Genomic and other biomarkers 
can stratify disease outcomes and susceptibility into subgroups that reflect the underlying 
disease heterogeneity and potential response to different types of interventions (1). For 
example, while implementing cholesterol education campaigns at the population level, 
individuals with familial hypercholesterolemia, a genetic disorder affecting 1 in 250 people, 
remain largely undiagnosed as they require more intense identification, high intensity LDL 
lowering drugs and cascade screening in families. Failure to ascertain this high-risk 
population subgroup of a million or more individuals in the United States, will lead to 
undertreatment and worse health outcomes (10), particularly as we miss the opportunity to 
implement evidence-based care for this subgroup. Another example is colorectal cancer 
screening. While evidence-based guidelines recommend colorectal cancer screening after 
age 50 in the “average” population, such guidelines will miss the 1 in 280 individuals with 
Lynch syndrome who are at increased risk of colorectal cancer and will require screening 
much earlier, requiring a more targeted approach to find these genetically high-risk 
individuals in the population and implement effective screening, follow-up and referral to 
care. (11)
More Precision Assessment by Time:
Big data may also improve precision through analysis of repeated measurements of the same 
variables over time. The use of personal devices such as sensors, smart phones and other 
digital devices (12) can provide measurement of variability over time, for various health 
indicators such as nutrition, physical activity, and blood pressure. Most surveys rely on 
infrequent or cross-sectional measurements of these and other health indicators. 
Smartphones are used increasingly to deliver evidence-based interventions (e.g. diet/
nutrition programs, psychotherapy, exercise). The data collected through digital devices 
gives a picture of how the interventions have been implemented and the outcomes generated 
with much greater precision.
Can big data inform next generation implementation studies?
Big data-driven public health assessment studies provide directions about how to enhance 
implementation in sub populations and can drive implementation studies that tailor 
interventions by place, persons and time.
More Precision Implementation by Place:
Implementation studies evaluate delivery of interventions in real-world contexts of health 
care delivery systems and communities, with the goal of delivering interventions optimally 
across populations. The use of machine learning and decision support tools (13) adapted to 
specific health care delivery systems could enhance implementation of evidence-based 
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guidelines. As discussed by Engelgau et al (14), tools of predictive analytics and big data 
can help identify major challenges for implementation including the identification of key 
barriers and facilitators within the socioecological context, various health and community 
policies, delivery strategies within health systems (e.g., physical infrastructure, availability 
of interventions), and community contexts (e.g., community resources, social deprivation, 
and economic issues). Predictive analytics based on big data offer new approaches to 
pinpoint key barriers and facilitators across the community context and lend insights into 
promising implementation strategies. (14)
More Precision Implementation by Person:
In order to reach subpopulations with unique health conditions, targeted intervention 
strategies will be needed. For example, the FH Foundation (https://thefhfoundation.org/) has 
developed a decision support tool using a machine-learning algorithm based on structured 
and unstructured data to help identify individuals with probable FH within electronic health 
records, large-scale laboratories and claims databases (15). The idea behind this and other 
similar tool is to aid clinicians to find more FH patients in selected populations, most of 
whom are currently undiagnosed and undertreated. Finding FH patients will also allow 
better implementation of recommended cascade screening in families.
More Precision Implementation by Time:
Smartphone apps can use big data to allow real-world collection and analysis over time for 
many evidence-based interventions (e.g., testing of adherence to medication use and longer-
term measuring of outcomes over time). Apps could serve as a microcosm of a learning 
system that collects data on person, place and time and use the patterns detected to adjust an 
intervention based on its overall pattern of use and effectiveness. For example, in a recent 
paper (16), a randomized clinical trial of 411 adults with poorly controlled hypertension 
showed that patients receiving a smartphone app used repeated measures to show a small 
improvement in reported adherence to medication use. This pilot study points to the need to 
evaluate more broadly the effects of mobile health interventions on implementation 
processes and clinical outcomes in order to understand the context of why some 
interventions successfully implement while others do not. Big data drawn from social media 
platforms are also increasingly used in the context of public health emergencies to enhance 
public health surveillance, detection of disease clusters, and facilitation of communication 
and behavior change to accelerate disease prevention and control. Dunn et al recently 
reviewed progress and promise of social media interventions that could enhance precision 
public health. They also cautioned about little we know about the health impact of such 
interventions and the risks of unintended consequences. (16)
There are immediate opportunities to explore how big data can influence the next generation 
of implementation science. For example, NCI recently put out a funding announcement to 
create a set of Implementation Science Centers for Cancer Control (17). This program will 
support rapid development and testing of innovative approaches to implement evidence-
based cancer control interventions; establish implementation laboratories in clinical and 
community sites; advance methods in studying implementation; and develop reliable 
implementation measures. (18) Implementation science centers will be an ideal forum for 
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using big data to accelerate implementation science in cancer control. These centers are 
expected to use multiple sources of data and develop implementation and outcome measures 
using a multi-level approach, including individual, family, school, workplace, social 
network, community, as well as natural, built, economic, policy, institutional and health care 
environments. Data will be integrated and captured across observational, self-report, 
objective and/or real time data to identify synergistic, complementary and interacting 
implementation research strategies.
Similarly, NHLBI is supporting implementation science to help turn discoveries into 
improved population health. This will require the collaboration of diverse stakeholders to 
leverage “expertise from biomedical, behavioral, and social science research, as well as 
experts from engineering, bioinformatics, behavior economics, and the emerging field of big 
data science (19).”
The crucial role and current challenges of machine learning and predictive 
analytics
To maximize the benefits of big data in precision public health, robust analytic methods are 
needed for individual studies and to synthesize information across studies (20). Machine 
learning and predictive analytic tools are increasingly used in healthcare and population 
health settings to make sense of the large amount of data, both for assessment and 
implementation purposes (21). In principle, predictive analytics can provide novel 
approaches to analyze disease prediction and forecasting models and to pinpoint key barriers 
and facilitators to delivery of proven effective interventions. The field of oncology provides 
a salient application of the big data analytics is how to combine data from multiple sources 
(DNA germ line and tumor sequencing, gene expression, epigenetics, proteomics, etc.) along 
with individual and population level variables in arriving at optimal and individualized 
intervention strategies both for treatment and prevention. Similar complex prediction models 
for heart disease prediction have been developed. For the most part, however, big data 
predictive analytics have not provided better quantitative risk prediction models when 
compared to classical statistical methods such as logistic regression analysis. (22)
There are numerous gaps and methodologic limitations that need to be overcome before big 
data can fulfill the promise of precision public health (21). Issues involving data inaccuracy, 
missing data, and selective measurement are substantial concerns that can potentially affect 
predictive modeling results and decision-making. In addition, deficiencies in model 
calibration can interfere with inferences. For example, patients may see multiple healthcare 
providers who use different health records in different health care delivery systems. Often, 
data are not shared across platforms, or are incomplete. Coding for health care billing also 
can vary from one system to another, and health records’ completeness can vary. This can 
potentially create biases in effect estimation and prediction modeling. Prediction models 
derived in one population may not be generalizable to other settings. Furthermore, 
methodologic deficiencies such as systematic bias in prediction models and non-
representative studies sets along with limited or differential access in subpopulations can 
contribute to widening of health disparities, especially for racial and ethnic minority 
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populations. For example, recent studies have consistently shown that the accuracy of 
genetic risk prediction models based on genome-wide association studies (GWAS) is less 
among non-European populations compared to European populations (23). This is due to the 
fact that most GWAS have been conducted in populations of European descent. The ultimate 
goal of big data analytics is to improve decision making both in clinical and population 
setting. Providing outcome probabilities may or may not change physician, patient or health 
system behavior. We need to evaluate the balance of benefits versus harms of specific 
implementation interventions (clinical utility).
As discussed in a special recent issue (24) on machine learning, predictive analytics need to 
have a clear purpose. Ideally, the development and validation of prediction models should 
strive for external validation. The current literature contains studies on machine learning 
approaches that have undergone retrospective testing but not prospective evaluation. 
Descriptive studies using existing data can identify barriers and facilitators to 
implementation. Interventions to address barriers are then integrated into prospective 
studies. As a result, the current applications of machine learning in health care systems 
remain severely limited (25). These limits also apply to public health activities that are 
concerned with implementation challenges and health outcomes in whole populations and 
subgroups that are outside the health care delivery system. This issue is especially relevant 
in dealing with global health data, and a large effort goes into knitting together disparate and 
noisy information to describe health outcomes and implementation challenges globally (25). 
Severe constraints on resources dictate the need to develop and evaluate alternative 
solutions. Issues of fairness, accountability, transparency, and privacy-preserving methods, 
and the anticipation of deleterious effects are essential considerations for ensuring that the 
promise of big data to improve health and reduce health disparities does not lead to 
unintended and opposite effects. (25)
Conclusions
In the age of genomics and big data, more extensive information by place, person and time 
are becoming available to measure public health impact and implementation needs. Using a 
few examples, we have shown how such data may provide more information derived from 
public health assessment studies and next generation of implementation studies. In principle, 
big data could point to implementation gaps and disparities and accelerate the evaluation of 
implementation strategies to reach population groups in most need for interventions. 
However, major challenges need to be overcome. For precision public health to succeed, 
further advances in predictive analytics, and practical tools for data integration and 
visualization need to be made. As most public health and implementation scientists are not 
well versed in big data science, it will be crucial to offer robust training and career 
development at the intersection of big data and public health. This research/training agenda 
will help turn the promise of big data into effective precision implementation strategies to 
maximize the benefits of evidence-based interventions to improve population health.
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